FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

Details on 22 Covid EUAs from 2023

Federal Register notice: FDA announces the issuance of Emergency Use Authorizations for 22 medical Covid-related medical devices authorized in 2023.

latest-news-card-1
Federal Register

Guide on GMPs for Veterinary APIs

Federal Register notice: FDA makes available a draft guidance entitled Good Manufacturing Practice for Active Pharmaceutical Ingredients (APIs) Used i...

latest-news-card-1
Biologics

Vitacell Biologics Illegally Selling Cellular Products: FDA

CBER says Lewisburg, TN-based Vitacell Biologics is illegally marketing cellular and exosome products.

Human Drugs

STAQ Pharma of Ohio FDA-483

FDA releases the form FDA-483 with two inspection observations issued to Columbus, OH-based STAQ Pharma of Ohio.

latest-news-card-1
Human Drugs

22 T-Cell Cancers After CAR-T Treatment: CBER

CBER executives say FDA is aware of a relatively small number of cases in which people treated with CAR-T products developed secondary cancers that ma...

latest-news-card-1
Human Drugs

Final ANDA Label Revision Guidance

FDA issues a finalized guidance on updating ANDA labels following revisions to the reference-listed drug label.

latest-news-card-1
Human Drugs

1st ISTAND Pilot AI Submission Accepted

CDER and CBER say they have accepted the first artificial intelligence, digital health technology, and neuroscience project in the ISTAND pilot for de...

latest-news-card-1
Animal Drugs

Animal Drug API GMP Guidance

FDA publishes a comprehensive Veterinary International Conference on Harmonization guidance on good manufacturing practice for animal drug APIs.

latest-news-card-1
Human Drugs

FDA Subscribes to digiM I2S Software

FDA purchases a subscription to digiM Solutions I2S software for the CDER Division of Product Quality and Research.

latest-news-card-1
Human Drugs

Stakeholder Input on Innovative Trial Workshop

Five stakeholders suggest possible topics for an upcoming FDA workshop on innovative drug clinical trials.